^
Association details:
| Biomarker: | SNX2-ABL1 fusion |
|---|---|
| Cancer: | Childhood B Acute Lymphoblastic Leukemia |
| Drug: | dasatinib (c-KIT inhibitor, Bcr-abl tyrosine kinase inhibitor, Src kinase inhibitor, EphA2 receptor antagonist, PDGFR β antagonist) |
| Direction: | Resistant |
Evidence:
Source:
Title:
Poor responses to tyrosine kinase inhibitors in a child with precursor B -cell acute lymphoblastic leukemia with SNX 2-ABL 1 chimeric transcript
Excerpt:
ALL cells carrying a SNX 2‐ABL 1 fusion exhibited a BCR ‐ABL 1 + ALL ‐like gene expression profile. The patient poorly responded to dasatinib but partially responded to imatinib.
DOI:
https://doi.org/10.1111/ejh.12234
